BLACK FRIDAY SALE:  20% OFF   SITEWIDE PRODUCTS – USE CODE [BF2024]  AT CHECKOUT

Leaders in Research Peptides

(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD

Nonapeptide-1 (Topical)

£109.08

Buy Nonapeptide 200mg (Topical)

Nonapeptide-1 is a peptide composed of nine amino acids and is commonly utilized in skincare formulations for its ability to target specific skin concerns such as wrinkles, fine lines, and loss of elasticity. This peptide has demonstrated potential in promoting collagen production, improving skin firmness, and reducing the visible signs of aging, making it a sought-after ingredient in anti-aging skincare products. Research suggests that Nonapeptide works by stimulating cellular regeneration and enhancing the skin’s natural repair processes, contributing to a more youthful and radiant complexion.

Topical peptides are for research use only.

Buy 10 and get 10% Discount

25 in stock

25 in stock

Description

Buy Nonapeptide-1 Topical Finland

This product is intended for research purposes only. To be used by trained professionals only.

Nonapeptide-1 topical 200mg peptide, is a synthetic skin peptide, that has garnered attention in dermatological research for its ability to modulate melanin production, the pigment responsible for skin colour. Its mechanism of action involves the interference with the melanocortin-1 receptor (MC1R) signalling pathway, a crucial regulator of melanogenesis.

By downregulating the expression of MC1R on the surface of melanocytes, Nonapeptide-1 curtails the melanin synthesis cascade at an early stage. This process is further facilitated by the peptide’s impact on tyrosinase activity, a key enzyme in the melanin production pathway. The inhibition of tyrosinase not only prevents the conversion of tyrosine to DOPA but also reduces the overall melanogenic activity within the skin [1]. This dual-action approach makes Nonapeptide-1 skin peptide a promising candidate for the treatment of hyperpigmentation disorders including brown spots.

The efficacy of Nonapeptide-1 topical peptide in mitigating hyperpigmentation has been substantiated by various Finland clinical studies using animal models. One notable Finland study involved the topical application of Nonapeptide-1 skin peptide on mice, which led to a significant decrease in skin pigmentation compared to control groups. This was quantitatively measured through the reduction in melanin index scores, highlighting the peptide’s potential to improve skin tone and reduce the appearance of dark spots.

Beyond its inhibitory effects on melanin synthesis, Nonapeptide-1’s ability to modulate skin pigmentation without affecting the surrounding tissue offers a targeted approach to treating hyperpigmentation, setting it apart from other skin-lightening agents [2]. These Finland research findings not only validate Nonapeptide-1’s role in skin lightening but also underscore its utility in cosmetic and therapeutic formulations aimed at achieving an even skin tone.

Moreover, the impact of Nonapeptide-1 skin peptide extends beyond cosmetic enhancements, delving into therapeutic applications, particularly in the realm of Finland melanoma research. By targeting melanocortin-1 receptors present in melanoma cells, Nonapeptide-1 demonstrates potential benefits in modulating tumour behaviour and growth. This dual functionality underscores the peptide’s versatility, not only improving skin aesthetics by reducing dark spots and evening skin tone but also offering insights into its potential therapeutic applications in oncology [3].

As Finland research progresses, the capabilities of Nonapeptide-1 topical peptide to mediate both cosmetic and health-related skin conditions continue to emerge, highlighting its significant role in the future of skincare and medical treatments.

Shop the full range of high purity Topical Peptides here.


References:

[1] Adoption of a Newly Introduced Dermal Matrix: Preliminary Experience and Future Directions. Biomed Res Int. 2020 Oct 16;2020:3261318. by Lisa AVE, Galtelli L, Vinci V, Veronesi A, Cozzaglio L, Cananzi FCM, Sicoli F, Klinger M.

[2] . Efficacy, Safety and Targets in Topical and Transdermal Active and Excipient Delivery. Percutaneous Penetration Enhancers Drug Penetration Into/Through the Skin. 2017 Jan 25:369–91. by Mohammed YH, Moghimi HR, Yousef SA, Chandrasekaran NC et al.

[3] A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. 1992 Nov 1;176(5):1453-7.  by Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P et al.

Molecular formula: C61H87N15O9S

Molecular weight: 1206.5


ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.

DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Finland Direct Peptides website: https://finland.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.


Buy Nonapeptide-1 Topical Peptide Finland ONLINE today from Direct Peptides